This strategy has precedent, says David Risinger of Morgan Stanley, but the scale and structure of Pfizer's scheme is unmatched.
ECONOMIST: Drugmakers
2.
David Risinger, the pharmaceuticals analyst at Morgan Stanley, made worries about the IMPROVE-IT result one of his key reasons for downgrading Merck shares.
FORBES: Merck To Pay $688 Million To Shareholders For Delaying Vytorin Results